Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
trBefBjtPTVFw1B6
Listen
